| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Guidelines for controlled trials of drugs in migraine: second edition.
|
Cephalalgia
|
2000
|
3.32
|
|
2
|
Headache recurrence after subcutaneous sumatriptan and early treatment.
|
Lancet
|
1992
|
2.08
|
|
3
|
Ergotamine in the acute treatment of migraine: a review and European consensus.
|
Brain
|
2000
|
1.52
|
|
4
|
[A vicious circle when headache medication is the cause of chronic headache. A well-planned ambulatory detoxication can result in dramatic improvement].
|
Lakartidningen
|
2001
|
1.38
|
|
5
|
Cardiac effects of beta-adrenergic receptor antagonists.
|
Adv Cardiol
|
1974
|
1.23
|
|
6
|
Attitudes and burden of disease among self-considered migraineurs--a nation-wide population-based survey in Sweden.
|
Cephalalgia
|
2004
|
1.15
|
|
7
|
Prevalence of perceived symptoms of dry mouth in an adult Swedish population--relation to age, sex and pharmacotherapy.
|
Community Dent Oral Epidemiol
|
1997
|
1.12
|
|
8
|
Studies on beta-adrenoceptor mediated facilitation of sympathetic neurotransmission.
|
Acta Physiol Scand Suppl
|
1981
|
1.04
|
|
9
|
Pre- and postjunctional effects of NPY on sympathetic control of rat femoral artery.
|
Acta Physiol Scand
|
1985
|
1.02
|
|
10
|
Role of the needling per se in acupuncture as prophylaxis for menstrually related migraine: a randomized placebo-controlled study.
|
Cephalalgia
|
2005
|
1.00
|
|
11
|
Neuropeptide Y (NPY): enhancement of blood pressure increase upon alpha-adrenoceptor activation and direct pressor effects in pithed rats.
|
Eur J Pharmacol
|
1985
|
1.00
|
|
12
|
Neuropeptide Y and sympathetic control of heart contractility and coronary vascular tone.
|
Acta Physiol Scand
|
1985
|
1.00
|
|
13
|
Increased noradrenaline release in rat portal vein during sympathetic nerve stimulation due to activation of presynaptic beta-adrenoceptors by noradrenaline and adrenaline.
|
Eur J Pharmacol
|
1978
|
0.98
|
|
14
|
Systemic absorption of adrenaline after aerosol, eye-drop and subcutaneous administration to healthy volunteers.
|
Allergy
|
1987
|
0.95
|
|
15
|
Assessing patient preference in migraine treatment.
|
Cephalalgia
|
2001
|
0.94
|
|
16
|
Impaired vasoconstrictor nerve function in spontaneously hypertensive rats after long-term treatment with propranolol and metroprolol.
|
Blood Vessels
|
1975
|
0.94
|
|
17
|
Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group.
|
Clin Ther
|
2000
|
0.92
|
|
18
|
Acyclovir concentrations in serum and cerebrospinal fluid at steady state.
|
J Antimicrob Chemother
|
1989
|
0.92
|
|
19
|
Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group.
|
J Neurol
|
1994
|
0.90
|
|
20
|
The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan.
|
Cephalalgia
|
2006
|
0.88
|
|
21
|
Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan.
|
Cephalalgia
|
2003
|
0.86
|
|
22
|
Plasma concentration-effect relationships of intravenous and extended-release oral felodipine in hypertensive patients.
|
J Cardiovasc Pharmacol
|
1990
|
0.85
|
|
23
|
Effects of the beta-adrenoceptor antagonists atenolol and propranolol on human whole saliva flow rate and composition.
|
Arch Oral Biol
|
1992
|
0.85
|
|
24
|
Assessment of health-related quality of life in migraine.
|
Cephalalgia
|
1993
|
0.84
|
|
25
|
Relationship between the overflow of endogenous and radiolabelled noradrenaline from canine blood perfused gracilis muscle.
|
Acta Physiol Scand
|
1984
|
0.84
|
|
26
|
Alpha 2-adrenoceptor-mediated inhibition of nerve stimulation-evoked release of neuropeptide Y (NPY)-like immunoreactivity in the pithed guinea-pig.
|
Eur J Pharmacol
|
1986
|
0.83
|
|
27
|
Negative feelings (discontent) predict progress of intima-media thickness of the common carotid artery in treated hypertensive men at high cardiovascular risk.
|
Am J Hypertens
|
1996
|
0.83
|
|
28
|
Pre- and postjunctional beta-adrenoceptor mediated effects on transmitter release and effector response in the isolated rat portal vein.
|
Acta Physiol Scand
|
1980
|
0.82
|
|
29
|
D-myo-inositol-1,2,6-trisphosphate is a selective antagonist of neuropeptide Y-induced pressor responses in the pithed rat.
|
Eur J Pharmacol
|
1991
|
0.82
|
|
30
|
Comparison of CNS-related subjective symptoms in hypertensive patients treated with either a new controlled release (CR/ZOK) formulation of metoprolol or atenolol.
|
J Clin Pharmacol
|
1990
|
0.81
|
|
31
|
Influence of acetylcholine, peptides, and other vasodilators on endogenous noradrenaline overflow and vasoconstriction in canine blood perfused gracilis muscle.
|
Acta Physiol Scand
|
1985
|
0.81
|
|
32
|
A low dietary sodium intake reduces neuronal noradrenaline release and the blood pressure in spontaneously hypertensive rats.
|
Naunyn Schmiedebergs Arch Pharmacol
|
1986
|
0.80
|
|
33
|
Evaluation and registration of adverse events in clinical drug trials in migraine.
|
Cephalalgia
|
2008
|
0.80
|
|
34
|
Quality of life is not negatively affected by diet and exercise intervention in healthy men with cardiovascular risk factors.
|
Qual Life Res
|
1995
|
0.80
|
|
35
|
Controlled-release metoprolol compared with atenolol in asthmatic patients: interaction with terbutaline.
|
Eur J Clin Pharmacol
|
1988
|
0.80
|
|
36
|
Neuropeptide Y (NPY) reduces field stimulation-evoked release of noradrenaline and enhances force of contraction in the rat portal vein.
|
Naunyn Schmiedebergs Arch Pharmacol
|
1985
|
0.80
|
|
37
|
Prejunctional beta 2-adrenoreceptor blockade reduces nerve stimulation evoked release of endogenous noradrenaline in skeletal muscle in situ.
|
Acta Physiol Scand
|
1987
|
0.80
|
|
38
|
Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack.
|
Cephalalgia
|
2006
|
0.80
|
|
39
|
Sumatriptan nasal spray (20 mg/dose) in the acute treatment of cluster headache.
|
Cephalalgia
|
1998
|
0.80
|
|
40
|
Withdrawal therapy improves chronic daily headache associated with long-term misuse of headache medication: a retrospective study.
|
Cephalalgia
|
2000
|
0.80
|
|
41
|
Heterogeneity of prejunctional neuropeptide Y receptors inhibiting noradrenaline overflow in the portal vein of freely moving rats.
|
Eur J Pharmacol
|
1994
|
0.79
|
|
42
|
Comparison of antihypertensive effect and pharmacokinetics of conventional and extended release felodipine tablets in patients with arterial hypertension.
|
Drugs
|
1987
|
0.79
|
|
43
|
Effects of the beta-adrenoceptor antagonists atenolol and propranolol on human parotid and submandibular-sublingual salivary secretion.
|
J Dent Res
|
1994
|
0.79
|
|
44
|
Neuropeptide Y (NPY) induced inhibition of preganglionic nerve stimulation evoked release of adrenalin and noradrenaline in the pithed rat.
|
Acta Physiol Scand
|
1988
|
0.78
|
|
45
|
CNS-related subjective symptoms during treatment with beta 1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies.
|
Br J Clin Pharmacol
|
1989
|
0.78
|
|
46
|
Tolerability and well-being with metoprolol in a controlled release (CR/ZOK) formulation: a review article.
|
J Clin Pharmacol
|
1990
|
0.78
|
|
47
|
A multinational investigation of the impact of subcutaneous sumatriptan. III: Workplace productivity and non-workplace activity.
|
Pharmacoeconomics
|
1997
|
0.78
|
|
48
|
Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks.
|
Cephalalgia
|
2002
|
0.78
|
|
49
|
Facilitation of nerve stimulation evoked noradrenaline overflow by isoprenaline but not by circulating adrenaline in the dog in vivo.
|
Life Sci
|
1987
|
0.78
|
|
50
|
A modified device for collection and flow-rate measurement of submandibular-sublingual saliva.
|
Scand J Dent Res
|
1993
|
0.77
|
|
51
|
The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial.
|
Cephalalgia
|
2001
|
0.77
|
|
52
|
Effects of the beta-adrenoceptor antagonists atenolol and propranolol on human unstimulated whole saliva flow rate and protein composition.
|
Scand J Dent Res
|
1994
|
0.77
|
|
53
|
Prejunctional alpha-adrenoceptor-mediated inhibition of norepinephrine release in blood-perfused skeletal muscle in situ.
|
J Cardiovasc Pharmacol
|
1987
|
0.77
|
|
54
|
Influence of metoprolol CR/ZOK on plasminogen activator inhibitor (PAI-1) in man: a pilot study.
|
J Clin Pharmacol
|
1990
|
0.77
|
|
55
|
Ethical aspects of placebo in migraine research.
|
Cephalalgia
|
2003
|
0.76
|
|
56
|
Effects on salivary flow rate and composition of withdrawal of and re-exposure to the beta 1-selective antagonist metoprolol in a hypertensive patient population.
|
Eur J Oral Sci
|
1996
|
0.76
|
|
57
|
Evidence for prejunctionally located beta 2-adrenoceptors in the cat spleen.
|
Naunyn Schmiedebergs Arch Pharmacol
|
1986
|
0.76
|
|
58
|
Migraine and beta-blockade: modulation of sympathetic neurotransmission.
|
Cephalalgia
|
1986
|
0.76
|
|
59
|
Central pre- and postsynaptic monoamine receptors in antidepressant therapy.
|
Acta Psychiatr Scand Suppl
|
1981
|
0.76
|
|
60
|
Pre- and postganglionic stimulation-induced noradrenaline overflow is markedly facilitated by a prejunctional beta 2-adrenoceptor-mediated control mechanism in the pithed rat.
|
Naunyn Schmiedebergs Arch Pharmacol
|
1994
|
0.76
|
|
61
|
Effects of beta-adrenoceptor antagonists on the firing rate of noradrenergic neurones in the locus coeruleus of the rat.
|
Naunyn Schmiedebergs Arch Pharmacol
|
1981
|
0.76
|
|
62
|
alpha- and beta-adrenoreceptor-mediated control of brain noradrenaline neurons and antihypertensive therapy.
|
Clin Sci (Lond)
|
1980
|
0.75
|
|
63
|
Effects of the thiazide diuretic bendroflumethiazide on salivary flow rate and composition.
|
Scand J Dent Res
|
1989
|
0.75
|
|
64
|
The SF-36 and the assessment of HRQoL.
|
Cephalalgia
|
1998
|
0.75
|
|
65
|
A multinational investigation of the impact of subcutaneous sumatriptan. I: Design, methods and clinical findings.
|
Pharmacoeconomics
|
1997
|
0.75
|
|
66
|
A multinational investigation of the impact of subcutaneous sumatriptan. IV: Patient satisfaction.
|
Pharmacoeconomics
|
1997
|
0.75
|
|
67
|
Adrenaline-induced enhancement of the blood pressure response to sympathetic nerve stimulation in adrenal demedullated pithed rats.
|
Naunyn Schmiedebergs Arch Pharmacol
|
1989
|
0.75
|
|
68
|
[Dynamic regulation of adrenergic receptors--stress, disease, drugs can affect their function].
|
Lakartidningen
|
1986
|
0.75
|
|
69
|
[After pharmacologic blood pressure treatment: only two in ten male hypertensive patients attain the recommended diastolic pressure].
|
Lakartidningen
|
1988
|
0.75
|
|
70
|
Headache recurrence after subcutaneous sumatriptan.
|
Lancet
|
1992
|
0.75
|
|
71
|
A randomized study of quality of life during multiple risk factor intervention in treated hypertensive men at high cardiovascular risk.
|
J Hypertens
|
1995
|
0.75
|
|
72
|
Effect of captopril on plasma levels of neuropeptide Y (NPY)-like immunoreactivity in the pithed guinea pig.
|
Neuropeptides
|
1991
|
0.75
|
|
73
|
Alpha- and beta-adrenoceptor-mediated effects on nerve stimulation-evoked release of neuropeptide Y (NPY)-like immunoreactivity in the pithed guinea pig.
|
J Auton Nerv Syst
|
1991
|
0.75
|
|
74
|
Long-term effects of diltiazem and atenolol on blood glucose, serum lipids, and serum urate in hypertensive patients. Swedish-Finnish Study Group.
|
Int J Clin Pharmacol Ther
|
1999
|
0.75
|
|
75
|
Oral mucosal friction and subjective perception of dry mouth in relation to salivary secretion.
|
Scand J Dent Res
|
1993
|
0.75
|